Thermoresponsive magnetoliposome encapsulating doxorubicin and high performance Ferumoxytol for effective tumor synergistic therapy in vitro

Abstract Owing to the multiple pathogenic routes and enormous proliferative capacity of tumor cells, conventional drug carriers find it difficult to fulfill clinical treatment gradually, for instance liposomes with single chemotherapy mode. New nanodrug carriers capable of multimodal therapy have emerged in an attempt to find an effective treatment; however, very few of them could be approved eventually, mainly because they could not reach the strict pharmaceutical quality standards. In this context, high-performance liposome synthesis based on typical medical materials may be an effective resolution strategy. Herein, a novel magnetoliposome coencapsulating doxorubicin and iron oxide nanomedicine Ferumoxytol was designed. After the formulation process screening, the magnetoliposome was found to be in stable dispersion with high Doxorubicin payload. In particular, a prominent magnetocaloric effect and thermoresponsive drug release profile were obtained. This is due to the combination of high performance Ferumoxytol with thermosensitive phospholipids dipalmitoylphosphatidylcholine. Compared with single hyperthermia or single chemotherapy, the chemotherapy and magnetic hyperthermia dual-modal synergetic treatment of the magnetoliposome present distinct advantages on cell viability assay in vitro. The novel temperature stimuli-responsive liposome enriches the anti-cancer nanomedicine species available in clinics, motivating the development of the clinical treatment strategy.